Kornimate/medical-research-clean huggingface dataset:
trauma-focused intervention with women experiencing homelessness

Conditions: Psychological Trauma; Trauma and Stress Related Disorders; Substance-Related Disorders; Substance Use; Substance Use Disorders

Summary: homelessness and associated traumas disproportionately affect women. the biopsychosocial health consequences of untreated trauma are profound. ptsd frequently co-occurs with other chronic health conditions, including substance use disorders (sud). co-morbid ptsd and sud (ptsd+sud) is common and difficult to treat, resulting in severe morbidity and premature mortality among women experiencing homelessness. executing this study will help to address the disproportionate ptsd+sud comorbidity burden, which drives health inequities in the growing population of women experiencing homelessness within and beyond chicago.

homelessness and associated traumas disproportionately affect women. the biopsychosocial health consequences of untreated trauma are profound. ptsd frequently co-occurs with other chronic health conditions, including substance use disorders (sud). co-morbid ptsd and sud (ptsd+sud) is common and difficult to treat, resulting in severe morbidity and premature mortality among women experiencing homelessness. we have systematically adapted a trauma-focused intervention protocol (narrative exposure therapy \[net\]) to the self-identified needs and preferences of trauma-affected women experiencing homelessness. this adapted intervention, "net+", incorporates strengths and preferences identified by women themselves, embedding principles of cognitive behavioral therapy (cbt) into conventional net. net+ aims to both employ core net principles to re-process past trauma in parallel with building present-centered skills to address avoidant coping motives in ptsd+sud. via a pragmatic, waitlist randomized controlled trial, we will further assess the feasibility, acceptability, and preliminary effects of a 3-week net+ intervention protocol with up to 100 women experiencing homelessness. we will determine pre- and post-net+ intervention ptsd and trauma-related symptom scores (depression, anxiety, somatization, sleep), substance use behaviors, and effect sizes. executing this study will help to address the disproportionate ptsd+sud comorbidity burden, which drives health inequities in the growing population of women experiencing homelessness within and beyond chicago.

Eligibility criteria:
inclusion criteria: * self-identifies as a woman; * greater than or equal to 18 years; * positive screen on taps-1 (reflecting problematic substance use); * recently (within 1 year) or currently homeless (hrsa definition); * affected by a traumatic life event and trauma-related distress (+life events checklist for dsm-5 standard \[lec-5\] response ≥1 and ptsd checklist for dsm-5 \[pcl-5\] score ≥28). exclusion criteria: - impaired decisional capacity to consent to participation (university of california, san diego brief assessment of capacity to consent \[ubacc\] score ≤14.5)

Keywords: homelessness
examining patient preferences about the ibm watson oncology clinical decision support system

Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer

Summary: the purpose of this study is to learn what cancer patients think about ibm watson oncology. ibm watson oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. the investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at msk in order to understand cancer patients' thoughts about ibm watson oncology.


Eligibility criteria:
inclusion criteria: * mskcc patient 18 years or older * breast, lung, or colorectal cancer msk patient as per emr or clinician judgment having either: * chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at msk * or chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at msk * or chemotherapeutic treatment through an on-going msk clinical trial as per clinician * residing in new york metro-area exclusion criteria: * non-english speakers because we do not have the resources to conduct and translate the focus groups into other languages * patients who are not or will not receive their cancer care at mskcc. * patient unwilling or unable to provide informed consent

Keywords: ibm watson clinical decision support system patient preferences 15-226
virtual reality technology for cerebral palsy

Conditions: Cerebral Palsy

Summary: the vrapeutic (full-immersive game-based therapy) is new therapeutic egyptian software. it has the potential to provide intensive, repetitive, and task-oriented training. it may increase children's motivation, enjoyment, active social participation. children with ucp may experience varieties of associated health conditions as difficulty of movement, instability of postural balance, difficulty of motor planning and control which impact on ue function.

ethical statement this study was approved by institutional review board of the faculty of physical therapy ,cairo university .egypt (no.p.t.rec/012/004237) . study design a prospective randomized controlled trial of pre-post study design with two months follow-up evaluation will be used. sample size estimation will be conducted to determine the number of recruited children. g\*power statistical software (version 3.1.9.2) will be used using α=0.05, power 80% allocation ratio n2/n1 =1. randomization the selected children will be assigned by simple randomization via closed envelopes into two equal groups (control and study); the envelope will be contained a letter indicating whether the child will be assigned to the control or to the study group.

Eligibility criteria:
inclusion criteria: * • their ages will range from of 6 to 10 years. * both genders will be included. * their degree of spasticity will range from 1 to 1+ according to the modified ashworth scale (meseguer et al., 2018). * their motor function will be at level i according to gross motor function classification system (palisano et al., 2008). * they will be able to understand and follow the instructions. exclusion criteria: * exclusion criteria: children will be excluded from the study if they have any of the following criteria: * epilepsy. * visual or hearing problems. * musculoskeletal fixed deformity in upper limbs, lower limbs or spine. * orthopedic surgery on the involved ue. * botulinum toxin therapy for the affected ue within the past 6 months or within the study period.

Keywords: virtual reality cerebralpalsy
uptake of genetic counseling among african american women

Conditions: Breast Cancer Risk

Summary: a feasibility study incorporating an educational intervention with cancer genetic risk assessment (cgra) in the ui health mammography center

african american (aa) women with a family history of breast cancer who are eligible for genetic counseling and express an interest in participating in the study will be consented and complete a brief survey before and after viewing an educational video on genetic counseling. survey questions will be read to each participant. the questions capture data on the following constructs regarding genetic counseling: knowledge, attitudes, normative beliefs, motivation, perceived social norms, intention, efficacy beliefs, skills, environmental constraints and opinions on the video. the research team will conduct a review of the ui health electronic medical record (emr) 3-6 months after study enrollment to determine if the participant attended a genetic counseling session.

Eligibility criteria:
inclusion criteria: * african american female age 25-69 years * presenting for mammogram at ui health mammography clinic * no prior history of breast cancer * completed cancer genetic risk assessment (cgra) in ui health mammography center * recommended for genetic counseling based on cgra performed at the time of the mammogram. exclusion criteria: * unable to complete the informed consent and survey in english * previously had genetic counseling for hereditary breast cancer risk * prisoners
treatment of degenerative disc disease with allogenic mesenchymal stem cells (msv)

Conditions: Degenerative Disc Disease; Intervertebral Disc Disease; Low Back Pain

Summary: in this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (msc), obtained from bone marrow of healthy donors, for treatment of degenerative disc disease (ddd). the trial is based in previous results with autologous msc (orozco et al., transplantation 92: 822-828; 2011). here we propose a phase i-ii trial, prospective, randomized, blinded, and controlled for the treatment ddd using msv, a good manufacturing practice (gmp)-compliant expanded bone marrow msc (msv, investigational medicinal product num. 10-134). the assay consists of two arms with 12 patients each one. patients in the experimental arm will be given a single intra-discal transplantation of msv (25 millions in 2 ml). control patients will be infiltrated in the paravertebral muscles close to the lesion with 2 ml of 1% mepivacain. we shall follow the evolution of pain, disability and quality of life as well as disc fluid content by magnetic resonance imaging (t2-calibrated).


Eligibility criteria:
inclusion criteria: * degenerative disease of one or two lumbar discs with predominant back pain after conservative treatment (physical and medical) for over 6 months. * fibrous ring capable of holding the cell implantation, demonstrated by magnetic resonance imaging (mri) image (stages 2, 3 and 4 of adams). * decrease of disc height of more than 20% (radiographic measurement in side image). * absence of spinal infection. * haematological and biochemical analysis wit no significant alterations that contraindicates intervention. * the patient is able to understand the nature of the study. * informed written consent of the patient. exclusion criteria: * age over 75 or under 18 or legally dependent * allergy to gentamicin, or to bovine, cattle or horse serum. * congenital or acquired diseases leading to spine deformations that may upset cell application. * spinal segmental instability, spinal canal stenosis, isthmus pathology and other conditions that may compromise the study * modic iii changes on mri images (31). * overweight with body mass index (mass in kg/size in m2) greater than 35 (obesity grade ii). * pregnancy or breast-feeding * neoplasia * immunosuppression * participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study. * other conditions that may, according to medical criteria, discourage participation in the study.

Keywords: degenerative disc disease, intervertebral disc disease low back pain nucleus pulposus stem cell cellular therapy regenerative therapy mesenchymal stem cells bone marrow musculoskeletal diseases mesenchymal stromal cells (allogenic)
evaluation of long-term safety and efficacy of elx/tez/iva in cystic fibrosis (cf) participants 2 years and older

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (elx)/tezacaftor (tez)/ivacaftor (iva) in cf participants 2 years of age and older.


Eligibility criteria:
key inclusion criteria: * completed study drug treatment in the parent study (vx20-445-111 part b, nct04537793), or had study drug interruption(s) in the parent study, but did not permanently discontinue study drug, and completed study visits up to the last scheduled visit of the treatment period of the parent study key exclusion criteria: * history of study drug intolerance in the parent study * history of poor compliance with elx/tez/iva and/or procedures in the parent study other protocol defined inclusion/exclusion criteria may apply
study evaluating the effectiveness of the use of prosthesis with trans-obturator way for the correction of anterior prolapse

Conditions: Anterior Prolapse

Summary: the classical surgical treatment of an anterior prolapse is the use of autologous tissue. in front of the high rate of recurrences with this technique, the use of synthetic prosthesis made their appearance. but the drawback of the use of prosthesis is their tolerability. the system perigee®, a prosthetic kit by trans-obturator way, was designed to obtain high efficiency in the correction of the prolapse while reducing the risk of complications. the lack of prospective and randomized studies makes difficult to assess the interest. the investigators, therefore, have put in place a randomized prospective study seeking the evaluation of the system perigee® compared to the conventional surgical technique.


Eligibility criteria:
inclusion criteria: * women over 18 years old * genital anterior prolapse requiring surgical correction and with stage iii or iv in the classification of pelvic organ prolapse - quantification or pop-q * ability to understand the information and to sign a consent form * patients wishing an intervention because of the inconvenience caused by the prolapse. exclusion criteria: * prolapse stage \<iii in the classification pop-q, and prolapse without functional inconvenience * progressive or latent infection, or signs of tissue necrosis in the clinical examination * troubles resulting in an unacceptable risk of post-surgery complications investigated at the interview with the patient (disorders of blood clotting, immune system disorders, progressive diseases....) * mobility of the lower limbs reduced (not permitting the positioning for the surgery) * pregnancy or any desire of pregnancy during the study, within two years * pelvic surgery in the last 6 months * patients who have had radiotherapy of the pelvic area in an irrespective time * a history of pelvic cancer * known hypersensitivity to any component of the prosthesis (polypropylene) * uncontrolled diabetes (hba1c\> 8%) * treatment modifying the immune response (immuno-modulators), current or stopped for less than one month * inability to understand the information and to sign a consent * a person not subject to social security, deprived of freedom, or under legal guardian

Keywords: correction of anterior prolapse prosthetic trans-obturator way kit randomized study
a study of obinutuzumab in combination with chop chemotherapy versus rituximab with chop in participants with cd20-positive diffuse large b-cell lymphoma (goya)

Conditions: Diffuse Large B-Cell Lymphoma

Summary: this open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (chop) chemotherapy versus rituximab (mabthera/rituxan) with chop in previously untreated participants with cluster of differentiation 20 (cd20)-positive diffuse large b-cell lymphoma (dlbcl). participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (iv) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) iv every 21 days for 8 cycles, in addition to 6-8 cycles of chop chemotherapy iv every 21 days. participants randomized to the obinutuzumab arm will receive an additional two doses on days 8 and 15 of cycle 1. anticipated time on study treatment is 24 weeks.


Eligibility criteria:
inclusion criteria: * previously untreated cd20-positive dlbcl * at least 1 bi-dimensionally measurable lesion (greater than \[\>\]1.5 centimeters \[cm\] in its largest dimension on the computed tomography \[ct\] scan) * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 * adequate hematological function * low-intermediate, high-intermediate or high-risk international prognostic index (ipi) score (low-risk ipi score: ipi 1 irrespective of bulky disease or ipi 0 with bulky disease, defined as one lesion greater than equal to (\>/=) 7.5 cm) * left ventricular ejection fraction (lvef) \>/=50 percent (%) on cardiac multiple-gated acquisition (muga) scan or cardiac echocardiogram exclusion criteria: * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of chop or obinutuzumab * contraindication to any of the individual components of chop, including prior receipt of anthracyclines * participants with transformed lymphoma and participants with follicular lymphoma iiib * prior therapy for dlbcl, with the exception of nodal biopsy or local irradiation * prior treatment with cytotoxic drugs or rituximab for another condition (for example, rheumatoid arthritis) or prior use of an anti-cd20 antibody * prior use of any monoclonal antibody within 3 months of the start of cycle 1 * corticosteroid use of \>30 milligrams per day (mg/day) of prednisone or equivalent, for purposes other than lymphoma symptom control * primary central nervous system (cns) lymphoma and secondary cns involvement by lymphoma, mantle-cell lymphoma (mcl), or histologic evidence of transformation to a burkitt lymphoma, primary mediastinal dlbcl, primary effusion lymphoma, plasmablastic lymphoma, and primary cutaneous dlbcl
cardiovascular risk and preventive care in prostate cancer patients receiving radiation and hormone therapy

Conditions: Prostate Cancer

Summary: this study will evaluate the proportion of prostate cancer patients receiving external beam radiation therapy (ebrt) and androgen deprivation therapy (adt) with controlled blood sugars (fasting glucose and hemoglobin a1c), blood pressure, and cholesterol profile (total cholesterol, ldl, hdl, triglycerides) at baseline, 3 months, and 12 months after completing radiation treatment. in addition, receipt of guideline-recommended cardiovascular, primary and preventive care as well as patient-reported quality of life and satisfaction with care among these patients will be evaluated at baseline and 12 months.


Eligibility criteria:
inclusion criteria: * histologically-confirmed, non-metastatic prostate cancer * patients who will receive external beam radiation treatment with androgen deprivation therapy (total adt duration \> 3 months) for curative treatment, either in the definitive or post-prostatectomy setting * patients who have a primary care provider * informed consent obtained and signed * ability to read and write english * age \>= 18 * no mental incompetence which would preclude completion of questionnaires exclusion criteria: * prior cancer, pelvic radiation treatment or chemotherapy * patients who do not have a primary care provider * prior adt * mental incompetence which would preclude completion of questionnaires * unable to read and write english

Keywords: prostate cancer external beam radiation treatment androgen deprivation therapy definitive treatment cardiovascular risk factors quality of life
growth curves in cockayne syndrome type 1 and type 2

Conditions: Cockayne Syndrome, Type I and II

Summary: despite the natural progression of cockayne's syndrome, affected patients also present with variable neurological and gastrointestinal damage (gastroesophageal reflux, recurrent vomiting, swallowing disorders, etc.) with varying repercussions on their growth. acute intercurrent events such as seizures, constipation, infections can also interact with their metabolism, food intake and influence their growth. the nutritional deficit potentially involved in this growth retardation can be responsible for many manifestations such as anemia, bone fractures, fatigue, coagulation disorders responsible in total for the reduction in quality and life expectancy. faced with growth retardation in patients with cockayne syndrome, medical management is difficult to establish. is this delay part of the natural course of the pathology?


Eligibility criteria:
inclusion criteria: * minor patient * cockayne syndrome with molecular confirmation, treated between 01/01/1985 and 01/03/2020 * collection of at least one growth data (height, weight, head circumference) for a given age * clinic compatible with type 1 or 2 cockayne syndrome * holder of parental authority not opposing, after information, the reuse of their child's medical data for the purposes of this scientific research. exclusion criteria: * refusal to participate in the study. * lack of molecular confirmation of cockayne syndrome * lack of growth data for a given age. * clinic not compatible with type 1 or 2 cockayne syndrome. exclusion of type 3 cockayne syndromes, trichothiodystrophy and xeroderma-pigmentosum.

Keywords: cockayne syndrome cockayne syndrome, type i and ii growth curves
art-pro: clinical trial evaluating biparametric mri and advanced, quantitative diffusion mri for detection of prostate cancer

Conditions: Prostate Cancer

Summary: this is a multicenter, multinational trial to evaluate advanced mri techniques for improved detection of clinically significant prostate cancer (cspca). the study will enroll 500 participants at 5 clinical centers (100 participants per center). the current standard mri technique for prostate cancer screening is multiparametric mri (mpmri), but two drawbacks include need for intravenous (iv) contrast and dependence on radiologist expertise. the investigators expect that the combination of two other techniques, biparametric mri (bpmri) and restriction spectrum imaging restriction score (rsirs), will help non-expert radiologists achieve similar performance to expert radiologists using bpmri or mpmri for detection of cspca, while avoiding the drawbacks that are present when using mpmri.

art-pro will be conducted in two phases (art-pro-1 and art-pro-2) and will evaluate bpmri, mpmri, and rsirs (an advanced quantitative diffusion technique), for detection of cspca. art-pro-1 will evaluate these techniques prospectively, by having each patients' mri exam read by 2 expert radiologists, both using different subsets of the images to evaluate the different techniques. art-pro-1 will additionally evaluate rsirs as a stand-alone quantitative biomarker. art-pro-2 will evaluate these same techniques retrospectively using radiologists of varying experience levels (novice, basic, and expert), and findings will be evaluated against the expertly created dataset from art-pro-1. patients will be followed after initial enrollment for the purpose of extracting relevant medical outcomes, such as biopsy results or surgery pathology.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * referred for mpmri of the prostate for suspicion of prostate cancer * mri is conducted using the standardized art-pro acquisition protocol exclusion criteria: * currently incarcerated * previous diagnosis of prostate cancer * active non-prostate tumor(s) in structures of the body near the prostate * previous prostate surgery * history of hip implant * metal implants or implanted devices in the body or other criteria that are deemed to require deviation from the usual acquisition protocol or scanning procedures

Keywords: prostate cancer multiparametric mri biparametric mri restriction spectrum imaging
preference of rheumatoid arthritis (ra) patients of enbrel® (etanercept) auto-injector versus enbrel® pre-filled syringes

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine the preference of ra patients for the new enbrel® (etanercept) pre-filled syringe in patients who are already taking enbrel®.


Eligibility criteria:
inclusion criteria: * have established ra diagnosis as determined by acr criteria * be current user of etanercept-lyophilized preparation for at least 4 consecutive weeks of etanercept dosing on either a once weekly or twice weekly regimen * subject must be able to self inject * give written informed consent exclusion criteria: * subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s) * subject of childbearing potential is pregnant (e.g., positive hcg test) or is breast-feeding * elective surgery is planned during study period * subjects allergic to latex

Keywords: arthritis rheumatology